Chemcrux Enterprises Ltd
Incorporated in 1996, Chemcrux Enterprises Ltd manufactures and processes bulk drug intermediates[1]
- Market Cap ₹ 136 Cr.
- Current Price ₹ 91.6
- High / Low ₹ 159 / 64.0
- Stock P/E 24.9
- Book Value ₹ 54.1
- Dividend Yield 1.09 %
- ROCE 8.89 %
- ROE 6.98 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 26.7%
Cons
- The company has delivered a poor sales growth of 9.14% over past five years.
- Company has a low return on equity of 8.01% over last 3 years.
- Working capital days have increased from 68.6 days to 100 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.60 | 20.09 | 27.43 | 31.45 | 55.27 | 57.45 | 53.33 | 95.27 | 95.15 | 78.47 | 70.25 | 82.58 | |
| 17.39 | 16.94 | 23.98 | 26.72 | 41.09 | 42.67 | 40.77 | 74.56 | 73.69 | 65.10 | 61.18 | 72.32 | |
| Operating Profit | 2.21 | 3.15 | 3.45 | 4.73 | 14.18 | 14.78 | 12.56 | 20.71 | 21.46 | 13.37 | 9.07 | 10.26 |
| OPM % | 11.28% | 15.68% | 12.58% | 15.04% | 25.66% | 25.73% | 23.55% | 21.74% | 22.55% | 17.04% | 12.91% | 12.42% |
| 0.06 | 0.07 | 0.31 | 0.29 | -0.30 | 0.90 | 0.84 | 1.00 | 1.05 | 1.18 | 1.53 | 2.67 | |
| Interest | 0.42 | 0.26 | 0.35 | 0.31 | 0.28 | 0.32 | 0.15 | 0.17 | 0.82 | 0.83 | 1.64 | 1.91 |
| Depreciation | 0.55 | 0.50 | 0.55 | 0.67 | 1.26 | 1.18 | 1.20 | 1.59 | 2.04 | 2.29 | 3.13 | 3.81 |
| Profit before tax | 1.30 | 2.46 | 2.86 | 4.04 | 12.34 | 14.18 | 12.05 | 19.95 | 19.65 | 11.43 | 5.83 | 7.21 |
| Tax % | 34.62% | 29.27% | 47.55% | 41.58% | 24.55% | 24.96% | 25.81% | 25.51% | 26.92% | 26.16% | 28.13% | 24.41% |
| 0.85 | 1.74 | 1.50 | 2.36 | 9.32 | 10.64 | 8.93 | 14.86 | 14.36 | 8.44 | 4.19 | 5.45 | |
| EPS in Rs | 1.57 | 3.22 | 1.01 | 1.59 | 6.30 | 7.19 | 6.03 | 10.03 | 9.70 | 5.70 | 2.83 | 3.68 |
| Dividend Payout % | 5.29% | 2.59% | 8.23% | 5.23% | 2.65% | 18.57% | 11.06% | 19.93% | 20.63% | 17.55% | 35.35% | 27.17% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 9% |
| 3 Years: | -5% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -9% |
| 3 Years: | -27% |
| TTM: | 37% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -36% |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 14% |
| 3 Years: | 8% |
| Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.80 | 1.80 | 4.94 | 4.94 | 4.94 | 4.94 | 4.94 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 |
| Reserves | 4.76 | 6.77 | 7.54 | 9.75 | 18.92 | 27.48 | 35.92 | 39.87 | 51.60 | 57.45 | 61.30 | 65.25 |
| 2.69 | 3.61 | 4.00 | 3.73 | 2.94 | 1.92 | 0.93 | 9.11 | 14.43 | 26.46 | 26.81 | 22.21 | |
| 4.62 | 2.96 | 4.11 | 8.37 | 11.81 | 10.20 | 6.90 | 19.32 | 12.38 | 11.15 | 9.23 | 15.42 | |
| Total Liabilities | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 112.15 | 117.69 |
| 7.07 | 7.54 | 8.29 | 10.75 | 11.24 | 15.40 | 19.37 | 24.32 | 33.11 | 33.09 | 57.55 | 56.18 | |
| CWIP | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.32 | 0.00 | 0.31 | 21.06 | 1.61 | 4.08 |
| Investments | 0.05 | 0.05 | 0.05 | 1.07 | 3.89 | 6.53 | 9.35 | 7.09 | 16.79 | 19.83 | 19.84 | 15.94 |
| 6.75 | 7.55 | 12.04 | 14.97 | 23.48 | 22.61 | 19.65 | 51.70 | 43.01 | 35.89 | 33.15 | 41.49 | |
| Total Assets | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 112.15 | 117.69 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.52 | 0.83 | 1.41 | 3.50 | 8.05 | 10.90 | 9.62 | 9.14 | 14.82 | 16.34 | 7.07 | 12.20 | |
| -0.72 | -0.97 | -1.45 | -4.17 | -5.18 | -7.62 | -8.16 | -2.64 | -20.48 | -25.89 | -7.93 | -2.28 | |
| -0.29 | -0.07 | 1.94 | -0.07 | -1.23 | -3.56 | -0.76 | 2.76 | 0.96 | 7.64 | -3.18 | -8.50 | |
| Net Cash Flow | 0.51 | -0.22 | 1.90 | -0.74 | 1.64 | -0.29 | 0.69 | 9.26 | -4.70 | -1.91 | -4.04 | 1.42 |
| Free Cash Flow | 0.82 | -0.14 | -0.04 | 0.36 | 5.56 | 5.53 | 3.46 | 4.57 | 3.71 | -6.85 | -1.01 | 7.29 |
| CFO/OP | 76% | 42% | 72% | 87% | 84% | 98% | 100% | 69% | 86% | 142% | 94% | 132% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 42.46 | 65.22 | 56.69 | 74.28 | 71.52 | 59.79 | 22.65 | 72.33 | 51.56 | 71.17 | 63.44 | 85.08 |
| Inventory Days | 104.29 | 74.71 | 105.14 | 111.70 | 71.92 | 84.82 | 137.46 | 92.33 | 124.92 | 99.63 | 127.16 | 59.69 |
| Days Payable | 73.69 | 38.26 | 54.75 | 131.52 | 75.76 | 46.42 | 15.85 | 92.57 | 71.19 | 70.84 | 52.84 | 88.21 |
| Cash Conversion Cycle | 73.06 | 101.68 | 107.07 | 54.46 | 67.67 | 98.19 | 144.26 | 72.09 | 105.28 | 99.96 | 137.76 | 56.57 |
| Working Capital Days | 8.94 | 21.80 | 34.20 | 43.17 | 47.68 | 52.48 | 67.69 | 37.51 | 67.28 | 55.49 | 50.09 | 100.24 |
| ROCE % | 18.58% | 25.85% | 22.26% | 24.81% | 58.78% | 46.03% | 31.55% | 37.64% | 27.75% | 13.46% | 7.11% | 8.89% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Permanent Employees Number |
|
|||||||||||
| Total Research & Development (R&D) Spend Rs. Lakhs |
||||||||||||
| Actual Production Volume (Oxidation, Nitration, Chloro Sulfonation) MT |
||||||||||||
| Total Installed Capacity (Oxidation, Nitration, Chloro Sulfonation) MT/Year |
||||||||||||
| Total Reaction Capability KL |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
23h - Newspaper Publication of Standalone and Consolidated Audited Financial Results for the quarter and year ended 31st March 2026.
-
Intimation Of Grant Of Stock Options Under Chemcrux Enterprises Employee Stock Option Scheme 2025 ("ESOP 2025" / "Scheme") - ESOP Grant 1 - 2026
1d - Chemcrux granted 107,700 stock options under ESOP 2025 on 14 May 2026, effective 15 May 2026.
-
Intimation U/R 30 Of SEBI (LODR) Regulations, 2013
1d - Kalichem Private Limited applied for CTE amendment at Moksi, Gujarat, to add inorganic chemicals.
-
Announcement under Regulation 30 (LODR)-Acquisition
1d - Board approved FY26 audited results, recommended 10% final dividend, and proposed CSR-focused WOS incorporation.
- Corporate Action-Board approves Dividend 1d
Business Overview:[1]
CEL is an ISO 9001:2015, ISO 14001:2015 and ISO 50001:2018 certified company. It specializes in High Pressure Oxidation, Nitration, Chlorosulfonation and Amidation Chemistry - manufacturing intermediates
for bulk drugs(API), dyes & pigment, electro-plating, pharmaceuticals, dyes and pigments industries